SCHEMBL1471586

SCHEMBL1471586

O=[N+]([O-])c1ccc(Oc2c(Cl)cc(S(=O)(=O)NC(=S)ONc3ccc(Cl)c(Cl)c3)cc2Cl)c(Cl)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRA P10827 3/20 0.52
CYP2C9 P11712 1/20 0.46
MEN1 O00255 5/20 0.45
KMT2A Q03164 5/20 0.45
GAA P10253 1/20 0.45
PKM P14618 1/20 0.45
FLT1 P17948 1/20 0.39
FLT4 P35916 1/20 0.39
KDR P35968 1/20 0.39
HSD17B10 Q99714 1/20 0.39
PDE7A Q13946 1/20 0.38
LGALS8 O00214 1/20 0.38
LGALS3 P17931 1/20 0.38
TBXA2R P21731 2/20 0.37
ALDH1A1 P00352 4/20 0.37
MAPT P10636 4/20 0.37
LMNA P02545 3/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
RAB9A P51151 1/20 0.36
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1471523 0.87 THRA (0.51) THRACYP2C9MEN1KMT2AGAA
SCHEMBL1472083 0.83 THRA (0.54) THRACYP2C9MEN1KMT2AGAA
SCHEMBL1471557 0.79 THRA (0.55) THRACYP2C9MEN1KMT2AGAA
SCHEMBL13485840 0.78 THRA (0.59) THRACYP2C9MEN1KMT2AGAA
SCHEMBL1471655 0.77 THRA (0.66) THRACYP2C9MEN1KMT2AGAA
SCHEMBL1471229 0.76 CYP2C9 (0.53) THRACYP2C9MEN1KMT2AGAA
SCHEMBL1473874 0.76 THRA (0.59) THRACYP2C9MEN1KMT2AGAA
SCHEMBL1471537 0.76 THRA (0.56) THRACYP2C9MEN1KMT2AGAA
SCHEMBL1474475 0.75 ALDH1A1 (0.55) THRACYP2C9MEN1KMT2AGAA
SCHEMBL1472164 0.75 CYP2C9 (0.60) THRACYP2C9MEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7915293-B2 Carbocyclic and heterocyclic sulfonamide derivatives, e.g., N-(2-bromo-5-(trifluoromethoxy)phenyl)-3,5-dichloro-4-(2-chloro-4-nitrophenoxy)benzenesulfonamide and 4-(2-(trifluoromethyl)phenoxy)-1-(3-trifluoromethyl)phenylsulfonyl)piperidine; treating proliferative diseases RIGEL PHARMACEUTICALS, INC. (US) 2011-03-29 US disclosed
US-20050009871-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. 2005-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009871-A1 Ubiquitin ligase inhibitors NEDD4, STUB1, UBE3A THRA 4803/4885CYP2C9 3737/4885MEN1 3441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.